share_log

SVB Leerink Maintains Market Perform on Innate Pharma, Raises Price Target to $7

Benzinga Real-time News ·  Mar 19, 2021 18:21

SVB Leerink analyst Daina Graybosch maintains Innate Pharma (NASDAQ:IPHA) with a Market Perform and raises the price target from $5 to $7.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment